Psychological Vulnerabilities and Transgender Adolescents: A Descriptive Epidemiology Study (VATED)

The number of adolescents engaging in a transidentity journey has been increasing rapidly over the last decade. However, the knowledge of the medical world concerning the specificities of these adolescents is still too little in France. The objective of this study is to refine the knowledge of the different health care providers who are brought to meet these adolescents. This research proposes to study more specifically the register of psychological vulnerabilities: to cite only a few examplesThese include disorders such as depression, anxiety disorders and eating disorders, all of which cause suffering and difficulties in everyday life. A better understanding of the presence or absence and the distribution of these different types of vulnerabilities among transgender adolescents would allow, among other things, to promote their their screening by health care providers. This better screening would allow doctors to physicians to offer targeted treatment for these disorders in parallel with the transition process. transition process.

Study Overview

• Status: Completed
• Conditions: Gender Dysphoria, Adolescent
• Intervention / Treatment: Diagnostic test: KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)

• Study Type: Observational
• Enrollment (Actual): 15

Contacts and Locations

Study Locations

• France
  • Toulouse, France
    • CHU Toulouse

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 18 years (ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

adolescents receiving follow-up in a specialized consultation on gender dysphoria

Description

Inclusion Criteria:

• Be between 12 and 18 years old
• Be followed up at the gender consultation of the Toulouse University Hospital

Exclusion Criteria:

• Have not yet completed the first consultation on gender issues at the time of selection.
• Have only one last appointment with the gender consultation at the time of selection

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
adolescents followed for gender dysphoria; The data collection by the examiner takes place during a single interview centered around the child's completion of a semi-structured questionnaire: the Kiddie Schedule for Affective Disorders and Schizophrenia. The child is interviewed alone and then with an accompanying parent.	Diagnostic test: KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia); completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
list of diagnoses of mental disorders	description of the prevalence of psychiatric comorbidities present in adolescents receiving follow-up in a specialized consultation on gender dysphoria using Diagnostic and Statistical Manual of Mental Disorders 5	enrollment

Collaborators and Investigators

• Sponsor: University Hospital, Toulouse
• Investigators: Principal Investigator: Sophie Çabal-Berthoumieu, MD, University Hospital, Toulouse

Study record dates

Study Major Dates

• Study Start (ACTUAL): November 26, 2021
• Primary Completion (ACTUAL): June 3, 2022
• Study Completion (ACTUAL): June 3, 2022

Study Registration Dates

• First Submitted: November 3, 2021
• First Submitted That Met QC Criteria: November 16, 2021
• First Posted (ACTUAL): November 18, 2021

Study Record Updates

• Last Update Posted (ACTUAL): July 29, 2022
• Last Update Submitted That Met QC Criteria: July 26, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: mental disorders
• Additional Relevant MeSH Terms: Mental Disorders; Sexual Dysfunctions, Psychological; Gender Dysphoria
• Other Study ID Numbers: RC31/21/0385

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No